Genocea Biosciences Logo
US3724274010
A2PK76
GNCA

Genocea Biosciences

Loading quotes...

Forecast

Buy
  1
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Genocea Biosciences had revenue of €1.44m and net profit of -€13.56m
(EUR) 2021
YoY
Revenue 1.44m 29.32%
Gross profit 1.44m 29.32%
Net profit -13.56m 62.22%
EBITDA -14.55m 57.00%

Fundamentals

Metric Value
Market capitalization
€0
52-week high/low
€1.32 - €0.0000908
Dividends No
Beta
0.00
P/E ratio
0.00
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

Name
Genocea Biosciences
CEO
William Clark
Headquarters Cambridge, ma
USA
Website
Sector
Consumer Staples
Industry
Food Products
IPO
05/02/2014
Employees 74

Ticker symbols

Exchange Symbol
NASDAQ
GNCA
London
0A51.L
🍪

Parqet  uses cookies. Learn more